Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement

Emma Kroeze(Princess Máxima Center), Laura Padilla(University Hospital Münster), Max Bakker(Princess Máxima Center), Judith M. Boer(Princess Máxima Center), Melanie M. Hagleitner(Princess Máxima Center), Birgit Burkhardt(University Hospital Münster), Takeshi Mori(Kobe Children's Hospital), Andishe Attarbaschi(St Anna Children's Hospital), Jaime Verdú‐Amorós(Hospital Clínico Universitario de Valencia), Marta Pillon(University of Padua), Liliya Anderzhanova(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Edita Kabíčková(Charles University), Aks Chiang(Queen Mary Hospital), Rejin Kebudi(Istanbul University), Karin Mellgren(Sahlgrenska University Hospital), Jelena Lazić(University of Belgrade), Janez Jazbec(Ljubljana University Medical Centre), Jules P.P. Meijerink(Princess Máxima Center), Auke Beishuizen(Princess Máxima Center), Jan Loeffen(Princess Máxima Center)
Cancers
August 12, 2022
Cited by 15Open Access
Full Text

Abstract

B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1−18 years (p = 0.0080), and that the outcome for infants (0−1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).


Related Papers